Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, the key interaction that drives infection.
As described in a recent pre-print on bioRxiv, this antibody did not show off-target binding to any human proteins on the MPA and is being progressed for further development.
Recent data show that as many as 25% of preclinical antibodies have off-target binding to unintended protein targets, which can lead to serious adverse events in patients.
The MPA is a collection of 6,000 membrane proteins expressed in live cells, representing nearly the entire human membrane proteome. The MPA provides specificity results in less than a month, faster than traditional non-clinical safety studies.
Rapidly eliminating drug candidates with off-target effects or other liabilities can accelerate the safe progression of therapeutics into the clinic.
With 20 years of excellence in virology research, Integral Molecular has quickly mobilized several of its technologies to combat COVID-19 and recently launched an antibody neutralization test using pseudotyped SARS-CoV-2 reporter viruses.
Integral Molecular is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses.
Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 300 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue.
Abound Bio is an early stage biotechnology company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease.
Abound Bio is led by world renowned experts in the therapeutic antibody, infectious disease, and cancer space with a significant track record of successful development of biotherapeutics, licensing, and partnerships.
Abound Bio's industry leading antibody libraries offer size and physical property advantages that incorporate diversified binder formats (Fab, scFv, VH) into the appropriate therapeutic platform (ADC, CAR, multispecific).
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes